Determination of fluoxetine in pharmaceutical and biological samples based on the silver nanoparticle enhanced fluorescence of fluoxetine–terbium complex. (2nd March 2016)

• Record Type: Journal Article
• Authors: Lotfi, Ali; Manzoori, Jamshid L.
• Is Part Of: Luminescence. Volume 31:Number 7(2016)
• Page Start: 1349
• Page End: 1357
• Publication Date: 2016-03-02
• Subjects: sensitized fluorescence -- terbium -- fluoxetine -- silver nanoparticles; Luminescence -- Periodicals; Bioluminescence -- Periodicals; Chemiluminescence -- Periodicals; Luminescence -- Periodicals; 535.35
• DOI: 10.1002/bio.3114
• Languages: English
• ISSNs: 1522-7235

Abstract

Abstract: In this study, a simple and sensitive spectrofluorimetric method is presented for the determination of fluoxetine based on the enhancing effect of silver nanoparticles (AgNPs) on the terbium–fluoxetine fluorescence emission. The AgNPs were prepared by a simple reduction method and characterized by UV–Vis spectroscopy and transmission electron microscopy. It was indicated that these AgNPs have a remarkable amplifying effect on the terbium‐sensitized fluorescence of fluoxetine. The effects of various parameters such as AgNP and Tb 3+ concentration and the pH of the media were investigated. Under obtained optimal conditions, the fluorescence intensity of the terbium–fluoxetine–AgNP system was enhanced linearly by increasing the concentration of fluoxetine in the range of 0.008 to 19 mg/L. The limit of detection ( b + 3 s ) was 8.3 × 10 ‐4 mg/L. The interference effects of common species found in real samples were also studied. The method had good linearity, recovery, reproducibility and sensitivity, and was satisfactorily applied for the determination of fluoxetine in tablet formulations, human urine and plasma samples. Copyright © 2016 John Wiley & Sons, Ltd.